DK2066352T3 - Behandling af multipel sklerose (ms) med campath-1h - Google Patents
Behandling af multipel sklerose (ms) med campath-1h Download PDFInfo
- Publication number
- DK2066352T3 DK2066352T3 DK07802348.8T DK07802348T DK2066352T3 DK 2066352 T3 DK2066352 T3 DK 2066352T3 DK 07802348 T DK07802348 T DK 07802348T DK 2066352 T3 DK2066352 T3 DK 2066352T3
- Authority
- DK
- Denmark
- Prior art keywords
- campath
- treatment
- days
- day
- treatment cycle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (6)
1. Anvendelse af Campath-1H til fremstilling af et medikament til reducering af risikoen for recidiv hos en patient, der har en recidiverende form af multipel sklerose (MS), som har modtaget tidligere behandling mod MS, hvor behandlingen med Campath-1H omfatter en første behandlingscyklus med Campath-1H efterfulgt af mindst én yderligere behandlingscyklus med Campath-1H, hvor hver behandlingscyklus omfatter 1-5 daglige doser, der gives på hinanden følgende dage, hvor den daglige dosis er >0 og < 12 mg, og hvor hver behandlingscyklus er adskilt fra den næste behandlingscyklus med mindst 1-24 måneder, hvor den første behandlingscyklus med Campath-1H administreres ved en dosis på 12 mg/dag i fem dage, og hvor patienten behandles igen 12 måneder efter den første behandlingscyklus med en yderligere behandlingscyklus med Campath-1H ved en dosis på 12 mg/dag i tre dage.
2. Anvendelse ifølge krav 1, hvor behandlingen med Campath-1H omfatter en første behandlingscyklus med Campath-1H på 12 mg/dag i fem dage og en anden behandlingscyklus med Campath-1H 12 måneder efter den første behandlingscyklus på 12 mg/dag i tre dage, hvor den første og anden behandlingscyklus kun følges af en tredje eller efterfølgende behandlingscyklus ved evidens for fornyet MS-aktivitet.
3. Anvendelse ifølge krav 2, hvor den tredje eller efterfølgende behandlingscyklus med Campath-1H er på 12 mg/dag i tre dage.
4. Campath-1H til anvendelse til reducering af risikoen for recidiv hos en patient, der har en recidiverende form af multipel sklerose (MS), som har modtaget tidligere behandling mod MS, hvor behandlingen med Campath-1H omfatter en første behandlingscyklus med Campath-1H efterfulgt af mindst én yderligere behandlingscyklus med Campath-1H, hvor hver behandlingscyklus omfatter 1-5 daglige doser, der gives på hinanden følgende dage, hvor den daglige dosis er >0 og < 12 mg, og hvor hver behandlingscyklus er adskilt fra den næste behandlingscyklus med mindst 1-24 måneder, hvor den første behandlingscyklus med Campath-1H administreres ved en dosis på 12 mg/dag i fem dage, og hvor patienten behandles igen 12 måneder efter den første behandlingscyklus med en yderligere behandlingscyklus med Campath-1H ved en dosis på 12 mg/dag i tre dage.
5. Campath-1H til anvendelse ifølge krav 4, hvor behandlingen med Campath-1H omfatter en første behandlingscyklus med Campath-1H på 12 mg/dag i fem dage og en anden behandlingscyklus med Campath-1H 12 måneder efter den første behandlingscyklus på 12 mg/dag i tre dage, hvor den første og anden behandlingscyklus kun følges af en tredje eller efterfølgende behandlingscyklus ved evidens for fornyet MS-aktivitet.
6. Campath-1H til anvendelse ifølge krav 5, hvor den tredje eller efterfølgende behandlingscyklus med Campath-1H er på 12 mg/dag i tre dage.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84425106P | 2006-09-13 | 2006-09-13 | |
| EP06090169 | 2006-09-14 | ||
| PCT/EP2007/008084 WO2008031626A1 (en) | 2006-09-13 | 2007-09-11 | Treatment of multiple sclerosis (ms) with campath-1h |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2066352T3 true DK2066352T3 (da) | 2016-02-29 |
Family
ID=38734000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07802348.8T DK2066352T3 (da) | 2006-09-13 | 2007-09-11 | Behandling af multipel sklerose (ms) med campath-1h |
Country Status (22)
| Country | Link |
|---|---|
| EP (4) | EP3028718B1 (da) |
| JP (6) | JP5872756B2 (da) |
| KR (2) | KR20150039879A (da) |
| CN (1) | CN102652832A (da) |
| AR (1) | AR062779A1 (da) |
| BR (1) | BRPI0716929A8 (da) |
| CA (1) | CA2662531A1 (da) |
| CY (1) | CY2016019I2 (da) |
| DK (1) | DK2066352T3 (da) |
| ES (2) | ES2563068T3 (da) |
| HK (1) | HK1136773A1 (da) |
| HR (1) | HRP20160211T1 (da) |
| HU (2) | HUE026740T2 (da) |
| IL (3) | IL197236A (da) |
| LT (1) | LTC2066352I2 (da) |
| LU (1) | LU93092I2 (da) |
| MX (2) | MX2009002660A (da) |
| PL (2) | PL2066352T3 (da) |
| PT (2) | PT3028718T (da) |
| RS (1) | RS54658B1 (da) |
| SI (1) | SI2066352T1 (da) |
| WO (1) | WO2008031626A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3028718B1 (en) | 2006-09-13 | 2022-03-23 | Alcafleu Management GmbH & Co. KG | Treatment of multiple sclerosis (ms) with campath-1h |
| US9498528B2 (en) | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
| TWI614267B (zh) | 2009-05-13 | 2018-02-11 | 建新公司 | 抗人類ｃｄ５２免疫球蛋白 |
| AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| JP7219721B2 (ja) * | 2017-04-21 | 2023-02-08 | ジェンザイム・コーポレーション | 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール |
| WO2020123789A1 (en) * | 2018-12-12 | 2020-06-18 | Pretzer Aboff Ingrid | Vibrational device and methods for mitigating symptoms of freezing of gait |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| EP3028718B1 (en) | 2006-09-13 | 2022-03-23 | Alcafleu Management GmbH & Co. KG | Treatment of multiple sclerosis (ms) with campath-1h |
-
2007
- 2007-09-11 EP EP15191491.8A patent/EP3028718B1/en active Active
- 2007-09-11 PL PL07802348T patent/PL2066352T3/pl unknown
- 2007-09-11 CN CN2012100864372A patent/CN102652832A/zh active Pending
- 2007-09-11 CA CA002662531A patent/CA2662531A1/en not_active Abandoned
- 2007-09-11 WO PCT/EP2007/008084 patent/WO2008031626A1/en active Application Filing
- 2007-09-11 MX MX2009002660A patent/MX2009002660A/es active IP Right Grant
- 2007-09-11 DK DK07802348.8T patent/DK2066352T3/da active
- 2007-09-11 BR BRPI0716929A patent/BRPI0716929A8/pt active Search and Examination
- 2007-09-11 HU HUE07802348A patent/HUE026740T2/en unknown
- 2007-09-11 ES ES07802348.8T patent/ES2563068T3/es active Active
- 2007-09-11 SI SI200731746A patent/SI2066352T1/sl unknown
- 2007-09-11 PT PT151914918T patent/PT3028718T/pt unknown
- 2007-09-11 KR KR20157007655A patent/KR20150039879A/ko not_active Application Discontinuation
- 2007-09-11 MX MX2013009511A patent/MX354080B/es unknown
- 2007-09-11 EP EP11189428A patent/EP2444104A3/en not_active Withdrawn
- 2007-09-11 KR KR1020097005111A patent/KR101583587B1/ko active IP Right Grant
- 2007-09-11 EP EP11189431A patent/EP2433649A3/en not_active Withdrawn
- 2007-09-11 RS RS20160081A patent/RS54658B1/en unknown
- 2007-09-11 JP JP2009527751A patent/JP5872756B2/ja active Active
- 2007-09-11 PL PL15191491.8T patent/PL3028718T3/pl unknown
- 2007-09-11 PT PT78023488T patent/PT2066352E/pt unknown
- 2007-09-11 EP EP07802348.8A patent/EP2066352B1/en active Active
- 2007-09-11 ES ES15191491T patent/ES2917882T3/es active Active
- 2007-09-13 AR ARP070104053A patent/AR062779A1/es not_active Application Discontinuation
-
2009
- 2009-02-25 IL IL197236A patent/IL197236A/en active IP Right Grant
-
2010
- 2010-02-26 HK HK10102029.9A patent/HK1136773A1/xx unknown
-
2013
- 2013-12-02 JP JP2013249139A patent/JP6257287B2/ja active Active
-
2015
- 2015-08-06 IL IL240394A patent/IL240394B/en active IP Right Grant
-
2016
- 2016-02-29 HR HRP20160211T patent/HRP20160211T1/hr unknown
- 2016-05-02 JP JP2016092377A patent/JP2016175929A/ja active Pending
- 2016-05-30 LT LTPA2016019C patent/LTC2066352I2/lt unknown
- 2016-05-30 HU HUS1600028C patent/HUS1600028I1/hu unknown
- 2016-05-31 LU LU93092C patent/LU93092I2/de unknown
- 2016-05-31 CY CY2016019C patent/CY2016019I2/el unknown
-
2017
- 2017-08-01 JP JP2017149006A patent/JP2018024655A/ja active Pending
-
2018
- 2018-02-04 IL IL257341A patent/IL257341A/en unknown
-
2019
- 2019-06-19 JP JP2019113260A patent/JP2019167385A/ja active Pending
-
2021
- 2021-04-14 JP JP2021068079A patent/JP2021107423A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20130108625A1 (en) | Treatment of multiple sclerosis (ms) | |
| JP2021107423A (ja) | カンパス−１Ｈ（Ｃａｍｐａｔｈ−１Ｈ）による多発性硬化症（ＭＳ）治療 | |
| AU2007296857B2 (en) | Treatment of multiple sclerosis (MS) with Campath-1H | |
| AU2016204844A1 (en) | Treatment of multiple sclerosis (MS) with Campath-1H | |
| AU2013206718A1 (en) | Treatment of multiple sclerosis (MS) with Campath-1H | |
| RU2574979C2 (ru) | Лечение рассеянного склероза (рс) | |
| TWI466683B (zh) | 多發性硬化症（ｍｓ）之治療 | |
| KR20220166827A (ko) | 혈청 IgG를 유지하면서 MS를 치료하기 위한 오파투무맙 | |
| US20230322942A1 (en) | Methods for treating multiple sclerosis with ocrelizumab | |
| KR20240107372A (ko) | 사트랄리주맙을 사용하는 중추 신경계(cns)의 탈수초화 질환의 치료 | |
| TW202337495A (zh) | 用satralizumab治療自體免疫腦炎 | |
| TW202330030A (zh) | 用ｓａｔｒａｌｉｚｕｍｂａ治療中樞神經系統（ｃｎｓ）之脫髓鞘疾病 | |
| AU2016319129A1 (en) | Methods for treating relapsing forms of multiple sclerosis |